(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/175924 Al 27 September 2018 (27.09.2018) W !P O PCT (51) International Patent Classification: (74) Agent: SCHER, Michael, B.; Johnson, Marcou & Isaacs, C07K 16/26 (2006.01) C07K 14/575 (2006.01) LLC, P.O. Box 691, Hoschton, GA 30548 (US). C07K 16/28 (2006.01) A61K 39/395 (2006.01) (81) Designated States (unless otherwise indicated, for every C07K 14/57 (2006.01) A61P 37/00 (2006.01) kind of national protection available): AE, AG, AL, AM, (21) International Application Number: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, PCT/US20 18/024082 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (22) International Filing Date: HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 23 March 2018 (23.03.2018) KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (25) Filing Language: English MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Langi English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (30) Priority Data: TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 62/476,352 24 March 20 17 (24 .03 .20 17) US (84) Designated States (unless otherwise indicated, for every 62/558,298 13 September 2017 (13.09.2017) US kind of regional protection available): ARIPO (BW, GH, (71) Applicants: THE BROAD INSTITUTE, INC. [US/US]; GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 415 Main Street, Cambridge, MA 02142 (US). UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, MASSACHUSETTS INSTITUTE OF TECHNOLO¬ TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, GY [US/US]; 77 Massachusetts Avenue, Cambridge, MA EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 02 139 (US). THE BRIGHAM AND WOMEN'S HOSPI¬ MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TAL, INC. [US/US]; 75 Francis Street, Boston, MA 021 15 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (US). KM, ML, MR, NE, SN, TD, TG). (72) Inventors; and Published: (71) Applicants: WALLRAPP, Antonia [US/US]; C/o 75 — with international search report (Art. 21(3)) Francis Street, Boston, MA 021 15 (US). RIESENFEILD, — before the expiration of the time limit for amending the Samantha, J. [US/US]; C/o 415 Main Street, Cambridge, claims and to be republished in the event of receipt of MA 02142 (US). BURKETT, Patrick, R. [US/US]; CI amendments (Rule 48.2(h)) o 75 Francis Street, Boston, MA 021 15 (US). KOWAL- — with sequence listing part of description (Rule 5.2(a)) CZYK, Monika, S. [US/US]; C/o 415 Main Street, Cam bridge, MA 02142 (US). REGEV, Aviv [US/US]; C/o 415 Main Street, Cambridge, MA 02142 (US). KUCHROO, Vijay, K. [US/US]; C/o 75 Francis Street, Boston, MA 021 15 (US). (54) Title: METHODS AND COMPOSITIONS FOR REGULATING INNATE LYMPHOID CELL INFLAMMATORY RESPONSES (57) Abstract: Computational and functional analysis identified the neuropep tide receptor Nmurl as selectively expressed on Type 2 innate lymphoid cells (ILC2s). While both IL-33 and IL-25 promote ILC activation in vivo, IL-33 in ■ ILC1 ILC2 duces robust ILC proliferation, whereas ILCs activated with IL-25 do not prolif □ Mixed None erate as robustly and up-regulate Nmurl expression. Treatment with neuromedin : 100 U (NMU), the neuropeptide ligand of Nmurl , had little effect on its own. Co-ad ministration of IL-25 with NMU, however, dramatically amplified allergic lung o 75 inflammation and induced the proliferation and expansion of specific ILC2 sub sets, characterized by a molecular signature unique to pro -inflammatory ILC2s. 50 The results demonstrate that Nmurl signaling strongly modulates IL-25-mediat- ed ILC2 responses, resulting in highly proliferative pro-inflammatory ILCs, and 25 highlights the importance of neuro-immune crosstalk in allergic inflammatory responses at mucosal surfaces. Control iL-25 IL-33 Condition METHODS AND COMPOSITIONS FOR REGULATING INNATE LYMPHOID CELL INFLAMMATORY RESPONSES CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims the benefit of U.S. Provisional Application Nos. 62/476,352, filed March 24, 2017 and 62/558,298, filed September 13, 2017. The entire contents of the above-identified applications are hereby fully incorporated herein by reference. STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH [0002] This invention was made with government support under grant numbers AI123516, AI056299 and AI039671 awarded by the National Institutes of Health. The government has certain rights in the invention. TECHNICAL FIELD [0003] The subject matter disclosed herein is generally directed to compositions and methods for modulating Type 2 innate lymphoid cell responses. BACKGROUND [0004] Type 2 innate lymphoid cells (ILC2s) regulate the initiation of allergic tissue inflammation at mucosal surfaces, in large part due to their ability to rapidly produce effector cytokines such as IL-5 and IL-13 14. ILC2s are also vital in maintaining tissue homeostasis by promoting epithelial cell proliferation, survival, and barrier integrity2. Alarmin cytokines, such as IL-25 and IL-33, activate ILC2s to promote tissue homeostasis in the face of epithelial injury, but also play critical roles in initiating allergic inflammatory responses6 9 10 . [0005] The factors that balance homeostatic and pathological ILC responses are unclear, and it remains unknown if unique subsets or functional states of ILCs mediate these homeostatic vs. pro inflammatory effects. Since there are no known markers of such functional states, it is also challenging to distinguish homeostatic from pro-inflammatory ILCs. Single-cell genomics, especially scRNA-seq 11'12, can help identify such diversity, even when changes in cell states are continuous across the cells in a population 13 , or are unique to a very small sub-population 14 15 . Recently, scRNA-seq-based approaches identified transcriptionally distinct sub-populations within intestinal ILC subsets, demonstrating the utility of scRNA-seq in identifying previously unrecognized subpopulations and cell states within this cell type, although the functional roles of these sub-populations remain to be clarified 16 . [0006] Citation or identification of any document in this application is not an admission that such document is available as prior art to the present invention. SUMMARY [0007] Type 2 innate lymphoid cells (ILC2s) are critical for maintaining mucosal barrier functions and tissue homeostasis, and yet are also important drivers of pathologic type 2 immune responses in allergy and asthma 1 5 . Alarmin cytokines produced by damaged and stressed epithelial cells, such as IL-25 and IL-33, have been shown to activate ILC2s, but it remains unclear if these cytokines are unique in switching homeostatic ILC2s into proinflammatory cells that drive tissue inflammation 6 8. [0008] It is an objective of the present invention to identify molecular cues that modulate ILC responses to alarmins. Applicants collected single-cell RNA-sequencing (scRNA-seq) profiles of lung-resident ILCs at steady state and after in vivo stimulation, combining massively-parallel droplet-based scRNA-seq surveys with full-length scRNA-seq for deeper characterization of markers. Computational and functional analysis identified the neuropeptide receptor Nmurl as selectively expressed on ILC2s. While both IL-33 and IL-25 promote ILC activation in vivo, IL-33 induces robust ILC proliferation, whereas ILCs activated with IL-25 do not proliferate as robustly and up-regulate Nmurl expression. [0009] It is another objective of the present invention to modulate ILC2 immune responses and cell states. Treatment of ILC2s with neuromedin U (NMU), the neuropeptide ligand of Nmurl, has little effect on its own in the experimental models used herein. Co administration of IL-25 with NMU, however, dramatically amplifies allergic lung inflammation and induces the proliferation and expansion of specific ILC2 subsets, characterized by a molecular signature unique to pro-inflammatory ILC2s. The results demonstrated for the first time that Nmurl signaling strongly modulates IL-25-mediated ILC2 responses, resulting in highly proliferative pro-inflammatory ILCs, and highlights the importance of neuro-immune crosstalk in allergic inflammatory responses at mucosal surfaces. [0010] In one aspect, the present invention provides for a method of treating a disease requiring reduction of an innate lymphoid cell (ILC) Type 2 inflammatory response comprising administering to a subject in need thereof a therapeutically effective amount of an agent capable of inhibiting neuromedin U receptor 1 (Nmurl) or blocking Nmurl interaction with neuromedin U (NMU). In a further aspect, the present invention provides for a method of reducing an innate lymphoid cell (ILC) Type 2 inflammatory response comprising administering to a subject in need thereof a therapeutically effective amount of an agent capable of inhibiting neuromedin U receptor 1 (Nmurl) or blocking Nmurl interaction with neuromedin U (NMU). Also provided is an agent capable of inhibiting neuromedin U receptor 1 (Nmurl) or blocking Nmurl interaction with neuromedin U (NMU) for use in a method of treating a disease requiring reduction of an innate lymphoid cell (ILC) Type 2 inflammatory response. Further provided is an agent capable of inhibiting neuromedin U receptor 1 (Nmurl) or blocking Nmurl interaction with neuromedin U (NMU) for use in reducing an innate lymphoid cell (ILC) Type 2 inflammatory response. Further provided is the use of an agent capable of inhibiting neuromedin U receptor 1 (Nmurl) or blocking Nmurl interaction with neuromedin U (NMU) for the manufacture of a medicament for treating a disease requiring reduction of an innate lymphoid cell (ILC) Type 2 inflammatory response.